---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005641"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:51:53.302356+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CNS Pharma Q2 net loss $4.0M; Berubicin GBM trial enrollment at 180; topline data expected Q4 2023

## Summary
- Net loss $4.0M for Q2 2023 vs $3.6M in Q2 2022; R&D expense $2.8M (up from $2.2M).
- Cash $4.3M as of June 30, sufficient into Q4 2023 through interim data readout.
- Berubicin GBM trial enrollment ~75% (180 of 240 patients); topline interim results expected Q4 2023.
- Company reiterated upcoming milestones: enroll 200th patient in Q3, complete enrollment in Q4.
- Investigation into naked short selling; believes majority of activity identified and eliminated.

## SEC filing metadata
- accession: 0001683168-23-005641
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/0001683168-23-005641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005641
- JSON: https://secwatch.observer/filing/0001683168-23-005641.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005641.txt

## Key facts
- Earnings Releases
  CNS Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income The net loss for the three months ended June 30, 2023 was approximately $4.0 million.
  - Period: the quarter ended June 30, 2023
  - Net income: The net loss for the three months ended June 30, 2023 was approximately $4.0 million
  - Result: reported results
  source text: On August 14, 2023, CNS Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the period ended June 30, 2023 and recent operational highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729427/000168316823005641/0001683168-23-005641-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.